[
    [
        {
            "time": "",
            "original_text": "华海药业：重组抗CD20人源化单克隆抗体注射液获临床试验批准",
            "features": {
                "keywords": [
                    "华海药业",
                    "重组抗CD20",
                    "人源化单克隆抗体",
                    "临床试验"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华海药业：重组抗CD20人源化单克隆抗体注射液获临床试验批准",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "上海医药：重组抗CD20人源化单克隆抗体注射液获得临床试验批准通知书",
            "features": {
                "keywords": [
                    "上海医药",
                    "重组抗CD20",
                    "人源化单克隆抗体",
                    "临床试验批准通知书"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "上海医药：重组抗CD20人源化单克隆抗体注射液获得临床试验批准通知书",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "上海医药(601607.SH)：“重组抗CD20人源化单克隆抗体注射液”将于近期启动Ib期临床试验",
            "features": {
                "keywords": [
                    "上海医药",
                    "重组抗CD20",
                    "人源化单克隆抗体",
                    "Ib期临床试验"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "上海医药(601607.SH)：“重组抗CD20人源化单克隆抗体注射液”将于近期启动Ib期临床试验",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "上海医药：重组抗CD20人源化单克隆抗体注射液获临床试验批准通知书",
            "features": {
                "keywords": [
                    "上海医药",
                    "重组抗CD20",
                    "人源化单克隆抗体",
                    "临床试验批准通知书"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "上海医药：重组抗CD20人源化单克隆抗体注射液获临床试验批准通知书",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业深度报告：创新药行业景气 医药新零售东风已起",
            "features": {
                "keywords": [
                    "医药生物",
                    "创新药",
                    "行业景气",
                    "医药新零售"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业深度报告：创新药行业景气 医药新零售东风已起",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]